-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 10, 2021, Genentech, a Roche subsidiary, announced that the new cancer immunotherapy tiragolumab targeting TIGIT, combined with the PD-L1 inhibitor atezolizumab, will be the first-line treatment for PD- Positive results were obtained in Phase 2 clinical trials in patients with L1-positive metastatic non-small cell lung cancer (NSCLC)
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is called T cell immunoglobulin and ITIM domain protein.
The latest results show that when the median follow-up time is 2.
In the intent-to-treat (ITT) population (n=67), compared with atelizumab monotherapy (median PFS=3.
An exploratory analysis performed in patients with high PD-L1 expression (TPS≥50%) (n=29) showed that compared with atelizumab monotherapy (median PFS=4.
In the secondary end point of the overall survival (OS) trial, the combination of tiragolumab/atelizumab also benefited the ITT population, with a median OS of 23.
The specific results of the test are shown in the following table:
Table source: Reference materials[1]
Dr.
Reference materials:
[1] New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech's Novel Anti-TIGIT Tiragolumab Plus Tecentriq.
